AIM ImmunoTech financials
$0.1735−5.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.0K | $22.0K | $21.0K | $26.0K | $25.0K | $16.0K | $45.0K | $35.0K | $50.0K | $40.0K | $65.0K | $46.0K |
| Gross profit | $21.0K | $18.0K | -$19.0K | -$42.0K | $15.0K | $6.0K | $38.0K | $27.0K | $42.0K | $32.0K | $53.0K | $16.0K |
| Gross margin | 80.8% | 81.8% | −90.5% | −161.5% | 60.0% | 37.5% | 84.4% | 77.1% | 84.0% | 80.0% | 81.5% | 34.8% |
| Operating income | -$3.5M | -$2.2M | -$3.0M | -$2.4M | -$2.6M | -$3.6M | -$5.9M | -$4.5M | -$3.7M | -$5.7M | -$14.0M | -$8.2M |
| Net income | -$7.0M | -$3.0M | -$4.2M | -$3.3M | -$2.8M | -$3.7M | -$6.0M | -$3.7M | -$1.8M | -$5.8M | -$12.6M | -$7.8M |
| Net margin | −26876.9% | −13740.9% | −19881.0% | −12630.8% | −11176.0% | −23156.3% | −13260.0% | −10571.4% | −3672.0% | −14542.5% | −19347.7% | −16991.3% |
| Diluted EPS | $-0.43 | $-0.69 | — | $-1.57 | $-3.68 | $-0.05 | $-0.03 | $-6.41 | $-3.47 | $-0.12 | $-0.26 | $-0.16 |
| EBITDA | -$3.0M | -$2.2M | -$2.9M | -$2.4M | -$2.3M | -$3.6M | -$5.9M | -$4.4M | -$3.6M | -$5.7M | -$14.0M | -$8.1M |
| Operating cash flow | -$4.6M | -$2.7M | -$2.0M | -$5.1M | -$1.5M | -$2.4M | -$4.0M | -$3.1M | -$3.0M | -$4.8M | -$9.8M | -$5.7M |
| Free cash flow | -$4.6M | -$2.7M | -$2.0M | -$5.1M | -$1.5M | -$2.4M | -$4.0M | -$3.1M | -$3.0M | -$4.8M | -$9.8M | -$5.7M |
| Diluted shares | 17.1M | 4.4M | — | 2.1M | 0.8M | 70.3M | 173.7M | 0.6M | 0.5M | 49.5M | 48.9M | 48.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.9M | $5.8M | $3.0M | $2.3M | $476.0K | $898.0K |
| Short-term investments | $64.0K | $63.0K | $62.0K | $62.0K | $359.0K | $1.3M |
| Total debt | $3.6M | $4.2M | $4.5M | $1.9M | $2.3M | $1.9M |
| Total assets | $12.7M | $8.6M | $5.8M | $5.5M | $4.1M | $6.2M |
| Total liabilities | $5.0M | $6.5M | $15.6M | $11.6M | $10.7M | $10.1M |
| Shareholders' equity | $7.7M | $2.1M | -$9.8M | -$6.1M | -$6.5M | -$3.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology